Comparative Pharmacology
Head-to-head clinical analysis: CLEMASTINE FUMARATE versus HYDRAMINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLEMASTINE FUMARATE versus HYDRAMINE.
CLEMASTINE FUMARATE vs HYDRAMINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clemastine fumarate is a competitive antagonist of histamine at H1-receptor sites, suppressing histamine-induced vasodilation, increased capillary permeability, bronchoconstriction, and pruritus. It also exhibits anticholinergic and sedative effects.
Antagonist of histamine H1 receptors, preventing histamine-mediated responses such as vasodilation, bronchoconstriction, and increased capillary permeability.
1.34 mg orally twice daily; max 8.04 mg/day
50-100 mg IV/IM every 4-6 hours, maximum 400 mg per day. Also available as 50 mg oral tablets.
None Documented
None Documented
Terminal elimination half-life: 21 ± 6 hours. Provides sustained antihistamine effect, allowing twice-daily dosing.
Clinical Note
moderateDiphenhydramine + Deferasirox
"The serum concentration of Deferasirox can be increased when it is combined with Diphenhydramine."
Clinical Note
moderateDiphenhydramine + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Fluticasone propionate."
Clinical Note
moderateDiphenhydramine + Tenofovir disoproxil
"The metabolism of Tenofovir disoproxil can be decreased when combined with Diphenhydramine."
Clinical Note
moderateTerminal elimination half-life 5.7 hours, range 4.2-7.7 hours; prolonged in hepatic impairment (up to 15 hours in cirrhosis)
Primarily renal (45-55% as unchanged drug and metabolites) and fecal (30-40%), with biliary excretion contributing minorly.
Primarily renal (95%) as metabolites; <5% unchanged; 5% fecal
Category C
Category C
Antihistamine
Antihistamine
Diphenhydramine + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Diphenhydramine."